Q-omics provides the consensus-scored PRKCZ-AS1 profile across patient tissues and cancer cell-line models. PRKCZ-AS1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRKCZ-AS1 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, PRKCZ-AS1 RNA expression shows 19,462 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LUAD, and ACC as cancer lineages where PRKCZ-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKCZ-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKCZ-AS1 survival associations across molecular data types. PRKCZ-AS1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKCZ-AS1 RNA expression–survival associations across cancer types. High PRKCZ-AS1 expression shows unfavorable associations in KIRC, ACC, KICH and COAD, but favorable associations in HNSC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRKCZ-AS1 RNA expression.
This table summarizes PRKCZ-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRKCZ-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKCZ-AS1 shows lower tumor expression in LUAD, KICH, UCEC, KIRC and BRCA and higher tumor expression in HNSC. The LUAD box plot shows higher PRKCZ-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.736, t-test p < 0.001).
This table shows molecular features associated with PRKCZ-AS1 in patient tissues and cancer cell lines. In patient samples, PRKCZ-AS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKCZ-AS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
